This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (26)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Alert me on articles by topic

David B. Clifford, MD

Arch Neurol. 2000;57:321-324.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Human immunodeficiency virus (HIV) enters the nervous system in the first hours of infection and remains present throughout the infection. Over the past 15 years, much has been learned about the neurologic complications of HIV infection, as well as secondary complications due to the development of opportunistic infections and increased risk of malignant neoplasms associated with the immunodeficient state. The increased risk of previously rare neurologic complications such as cryptococcal meningitis, toxoplasma encephalitis, and progressive multifocal leukoencephalopathy has permitted refinement of therapeutic stratagems for the treatment of these complications. While these are important issues, the fundamental neurologic problem is understanding the pathophysiology of the HIV infection in the brain so as to optimally treat this critical manifestation of acquired immunodeficiency sydrome (AIDS). Clinical observations and formal trials are contributing to the increasing knowledge about HIV disease in the brain.

CLINICAL FORMS OF HIV NEUROLOGIC DISEASE

During primary infection, typical "aseptic meningitis" often . . . [Full Text of this Article]

HIV ANTIVIRAL THERAPY AND HAD

CONTROLLED TRIALS FOR THERAPY IN HAD

PATHOPHYSIOLOGICALLY TARGETED THERAPY FOR HAD

SUMMARY

From the Department of Neurology, Washington University School of Medicine, St Louis, Mo.

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2000;57(3):430-432.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment
Clifford et al.
Neurology 2002;59:1568-1573.
ABSTRACT | FULL TEXT  

Risk Factors for Cognitive Impairment in HIV-1-Infected Persons With Different Risk Behaviors
De Ronchi et al.
Arch Neurol 2002;59:812-818.
ABSTRACT | FULL TEXT  

Clinical and spectroscopic improvement in HIV-associated cognitive impairment
Stankoff et al.
Neurology 2001;56:112-115.
ABSTRACT | FULL TEXT